Ventas, Inc. (VTR - Free Report) reported fourth-quarter 2016 normalized funds from operations (“FFO”) of $1.03 per share, in line with the Zacks Consensus Estimate. The bottom-line figure for the prior-year quarter was also $1.03.
The bottom line for full-year 2016 came in at $4.13 per share, in line with the Zacks Consensus Estimate. The full-year 2015 FFO was $3.95 per share.
The company posted revenues of $875.7 million in the fourth quarter, which beat the Zacks Consensus Estimate of $843 million. Further, it compared favorably with the year-ago tally of $841.3 million.
For full-year 2016, revenues came in at $3.44 billion, up from the 2015 tally of $3.29 billion.
Modest NOI Growth
For the fourth quarter, same-store cash net operating income (“NOI”) growth for total portfolio (1,189 assets) was 2.9% on a reported basis. Notably, triple net same-store cash NOI grew 4.5%, the seniors housing operating portfolio same-store NOI grew 1.1% and the medical office building portfolio rose 2.1%.
Notable Portfolio Activity
The company expects to close its $700 million loan commitment to fund Ardent Health Services’ acquisition of LHP Hospital Group late in first-quarter 2017.
In Jan 2017, Ventas sold assets and received final repayment on loans receivable for proceeds of $88 million.
Liquidity
Presently, the company has more than $2 billion available under its revolving credit facility and $286.7 million of cash or cash equivalents in hand.
2017 Outlook
The company anticipates same-store cash net operating income growth of 1.5–2.5% in 2017.
Further, Ventas expects dispositions of $900 million in 2017. It intends to use the net proceeds to expand the company’s life science and acute care hospital platforms and for debt repayment.
Our Take
Going forward, we believe that Ventas’ adequate size and scale would help it capitalize on opportunities such as increasing healthcare spending, aging population and a rise in insured individuals. Yet, stiff competition and a projected rise in interest rates keep us concerned.
Currently, Ventas carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We now look forward to the earnings releases of DDR Corp. , Vornado Realty Trust (VNO - Free Report) and HCP, Inc. (HCP - Free Report) which are expected next week.
Note: All EPS numbers presented in this write-up represent funds from operations (“FFO”) per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Zacks’ Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Ventas, Inc. (VTR - Free Report) reported fourth-quarter 2016 normalized funds from operations (“FFO”) of $1.03 per share, in line with the Zacks Consensus Estimate. The bottom-line figure for the prior-year quarter was also $1.03.
The bottom line for full-year 2016 came in at $4.13 per share, in line with the Zacks Consensus Estimate. The full-year 2015 FFO was $3.95 per share.
The company posted revenues of $875.7 million in the fourth quarter, which beat the Zacks Consensus Estimate of $843 million. Further, it compared favorably with the year-ago tally of $841.3 million.
For full-year 2016, revenues came in at $3.44 billion, up from the 2015 tally of $3.29 billion.
Modest NOI Growth
For the fourth quarter, same-store cash net operating income (“NOI”) growth for total portfolio (1,189 assets) was 2.9% on a reported basis. Notably, triple net same-store cash NOI grew 4.5%, the seniors housing operating portfolio same-store NOI grew 1.1% and the medical office building portfolio rose 2.1%.
Notable Portfolio Activity
The company expects to close its $700 million loan commitment to fund Ardent Health Services’ acquisition of LHP Hospital Group late in first-quarter 2017.
In Jan 2017, Ventas sold assets and received final repayment on loans receivable for proceeds of $88 million.
Liquidity
Presently, the company has more than $2 billion available under its revolving credit facility and $286.7 million of cash or cash equivalents in hand.
2017 Outlook
The company anticipates same-store cash net operating income growth of 1.5–2.5% in 2017.
Further, Ventas expects dispositions of $900 million in 2017. It intends to use the net proceeds to expand the company’s life science and acute care hospital platforms and for debt repayment.
Our Take
Going forward, we believe that Ventas’ adequate size and scale would help it capitalize on opportunities such as increasing healthcare spending, aging population and a rise in insured individuals. Yet, stiff competition and a projected rise in interest rates keep us concerned.
Currently, Ventas carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We now look forward to the earnings releases of DDR Corp. , Vornado Realty Trust (VNO - Free Report) and HCP, Inc. (HCP - Free Report) which are expected next week.
Note: All EPS numbers presented in this write-up represent funds from operations (“FFO”) per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Zacks’ Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on VTR - FREE
Get the latest research report on HCP - FREE
Get the latest research report on VNO - FREE